This review highlights current interventional clinical trials for HIV-associated malignancies
(HIVAMs), with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene …

For people living with HIV, recent years have seen striking advances in the range of
antiretroviral therapies available, our understanding of the optimal application of these …

Because of tremendous advances in HIV care, the survival of many people living with HIV
(PLWH) now approaches that of the general population. This has led to a shift in the types of …

A curative strategy in HIV will likely need to both reduce the amount of virus that persists on
antiretroviral therapy and improve anti-HIV immune surveillance. Although we continue to …

Abstract According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), as of
2019, approximately 42.2 million people have died from acquired immunodeficiency …

Interpretation of clinical trials to guide therapy for those with HIV infection and cancer largely
depends on data that does not include HIV-infected patients. The ability to extend clinical …

Cancer is the leading cause of death for HIV-infected persons in economically developed
countries, even in the era of antiretroviral therapy (ART). Lymphomas remain a leading …

In the 1980s, infection by the human immunodeficiency virus (HIV) was a devastating
condition, signifying near-certain lethality; however, people infected by HIV today may have …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Background: Patients infected with HIV have an 8 to 150-fold risk of lymphoma compared to
HIV uninfected patients, with certain aggressive non-Hodgkin lymphoma (NHL) histologies …